<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914691</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000335-32</org_study_id>
    <nct_id>NCT02914691</nct_id>
  </id_info>
  <brief_title>Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes</brief_title>
  <acronym>DapKid</acronym>
  <official_title>Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Rossing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: SGLT2 inhibitors are the first antiglycaemic drugs with a direct renal action. A&#xD;
      part from reducing blood glucose, systemic blood pressure and albuminuria are decreased,&#xD;
      while natriuresis is increased.&#xD;
&#xD;
      Previous research into urinary peptide patterns (proteomics) has revealed that patients in&#xD;
      risk of progressive renal disease display a &quot;risk peptide pattern&quot; in their urine, ahead of&#xD;
      decline in renal function. Furthermore a urinary proteome pattern is related to CVD risk.&#xD;
&#xD;
      The long-term impact of dapagliflozin (dapa) treatment on renal parameters is unknown, but&#xD;
      long term randomized trials are ongoing. By investigating the impact of dapa treatment on&#xD;
      this peptide pattern, it will be determined whether this intervention can improve the urinary&#xD;
      proteomic peptide pattern. In addition new knowledge regarding renal processes that the&#xD;
      treatment influences is sought.&#xD;
&#xD;
      The impact of treatment of urinary and tubular markers of oxidative stress and function&#xD;
      (metabolomics) will be assessed. These markers are thought to represent one of several&#xD;
      deleterious pathways involved in the pathology of diabetic renal disease, and here the impact&#xD;
      dapa treatment will be investigated. Improvement of these markers of oxidative stress may&#xD;
      indicate long-term benefit.&#xD;
&#xD;
      Objective: The primary objective is to assess the impact of three months of treatment with&#xD;
      dapa 10 mg once daily or placebo on renal proteomics pattern and other risk markers of&#xD;
      diabetic comorbidity.&#xD;
&#xD;
      Design: Double blinded, randomized, placebo-controlled crossover, single center study.&#xD;
      Treatment period: 2 x 12 weeks.&#xD;
&#xD;
      Patient population: 40 patients with type 2 diabetes recruited from Steno Diabetes Center in&#xD;
      accordance with the study in- and exclusion criteria.&#xD;
&#xD;
      Intervention: Dapa 10 mg daily vs. placebo. Endpoints: Primary outcome: To evaluate the&#xD;
      effect of dapa treatment on urinary proteomic patterns in patients with type 2 diabetes,&#xD;
      microalbuminuria and eGFR equal to or above 45 ml/min/1.73m2.&#xD;
&#xD;
      Secondary endpoints are the effect of the intervention on other markers for tubular function,&#xD;
      inflammation, endothelial dysfunction, microcirculation, kidney function, albuminuria,&#xD;
      vasoactive hormones in plasma, and effect on global longitudinal strain as measured by&#xD;
      echocardiography.&#xD;
&#xD;
      Timeframe: Randomisation planned from June 2015, inclusion over the following 9 months. Last&#xD;
      patient is expected to be completed October 2016. Data analysis completed December 2016,&#xD;
      presentation autumn 2017 and publication early 2018.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">July 5, 2017</completion_date>
  <primary_completion_date type="Actual">July 5, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urinary Peptide Patterns (Proteomics)</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Proteomics will be evaluated at week 0, at crossover week 12 (+/- 1 week), and at end study week 24 (+/- 1 week)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin 10 mg once daily tablet treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical once daily tablet treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozine 10 mg once daily tablet treatment</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical once daily tablet treatment</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients &gt;18 years of age with a diagnosis of type 2 diabetes (WHO&#xD;
             criteria).&#xD;
&#xD;
          -  Patients must be on current stable antiglycaemic treatment with oral drugs (OAD) or&#xD;
             insulin 4 weeks before start of study drug and throughout study duration.&#xD;
&#xD;
          -  Patients must be on stable antihypertensive treatment (must include renin-angiotensin&#xD;
             system blocking treatment) 4 weeks before start of study drug and throughout study&#xD;
             duration.&#xD;
&#xD;
          -  HbA1c &gt;7.5 %&#xD;
&#xD;
          -  Urinary albumin creatinine ratio (UACR) &gt; 30 mg/g (in ≥2 out 3 morning spot urine&#xD;
             collections prior to randomisation).&#xD;
&#xD;
          -  eGFR ≥ 45 ml/min/1.73 m2&#xD;
&#xD;
          -  Stable RAAS-blocking treatment (more than or equal to 4 weeks prior to visit 0) If not&#xD;
             stable at visit 0, screening phase can be prolonged to 4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treatment with loop diuretics&#xD;
&#xD;
          -  Current treatment with thiazolidinediones&#xD;
&#xD;
          -  Current treatment with dapagliflozin or other SGLT2 inhibitor&#xD;
&#xD;
          -  Ongoing cancer treatment&#xD;
&#xD;
          -  Patients on hypertension treatment who are is not on stable antihypertensive treatment&#xD;
             (must include renin-angiotensin system blocking treatment) 4 weeks before start of&#xD;
             study drug and throughout study duration&#xD;
&#xD;
          -  Severe hepatic insufficiency and/or significant abnormal liver function defined as&#xD;
             aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or alanine&#xD;
             aminotransferase (ALT) &gt;3x ULN&#xD;
&#xD;
          -  Total bilirubin &gt;2.0 mg/dL (34.2 µmol/L)&#xD;
&#xD;
          -  Positive serologic evidence of current infectious liver disease including, Hepatitis B&#xD;
             surface antigen and antibody and Hepatitis C virus antibody&#xD;
&#xD;
          -  eGFR: &lt;45 mL/min (calculated by MDRD formula)&#xD;
&#xD;
          -  History of unstable or rapidly progressing renal disease&#xD;
&#xD;
          -  Volume depleted patients. Patients at risk for volume depletion due to co-existing&#xD;
             conditions or concomitant medications, such as loop diuretics should have careful&#xD;
             monitoring of their volume status&#xD;
&#xD;
          -  Recent Cardiovascular Events in a patient:&#xD;
&#xD;
             1. Acute Coronary Syndrome (ACS) within 2 months prior to enrolment 2.Hospitalization&#xD;
             for unstable angina or acute myocardial infarction within 2 months prior to enrolment&#xD;
             3. Acute Stroke or TIA within two months prior to enrolment 4. Less than two months&#xD;
             post coronary artery revascularization&#xD;
&#xD;
          -  Congestive heart failure defined as New York Heart Association (NYHA) class IV,&#xD;
             unstable or acute congestive heart failure. Note: eligible patients with congestive&#xD;
             heart failure, especially those who are on diuretic therapy, should have careful&#xD;
             monitoring of their volume status throughout the study.&#xD;
&#xD;
          -  Pregnant or breastfeeding patients&#xD;
&#xD;
          -  Patients who, in the judgement of the investigator, may be at risk for dehydration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter Rossing</investigator_full_name>
    <investigator_title>Professor, MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

